OCUSULF-30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUSULF-30 (OCUSULF-30).
Unoprostone is a docosanoid that lowers intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork and uveoscleral pathways. It acts as a prostaglandin F2α analog with activity at the FP receptor, though the exact molecular mechanism is not fully characterized.
| Metabolism | Unoprostone is metabolized by 15-hydroxyprostaglandin dehydrogenase and undergoes β-oxidation and ω-oxidation. The primary metabolite is unoprostone free acid. |
| Excretion | Renal excretion as unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion contributes 20-30% with minor metabolism. |
| Half-life | Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-60 mL/min), requiring dose adjustment. |
| Protein binding | Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2-1.6 L/kg, indicating extensive extravascular distribution with tissue penetration. |
| Bioavailability | Oral: 75-85% (first-pass metabolism minimal); Sublingual: 90-95%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours. Duration extends in hepatic impairment. |
| Molecular Weight | 500 |
In adults, the typical dose of OCUSULF-30 is 30 mg intraocular injection once daily for 7 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | For GFR 30-60 mL/min: reduce dose to 15 mg once daily. For GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce dose to 15 mg once daily. Class C: not recommended. |
| Pediatric use | Not approved for pediatric use; no established dosing guidelines. |
| Geriatric use | No specific dose adjustment required, but monitor renal function due to age-related decline. |
| 1st trimester | Avoid due to potential fetal toxicity. |
| 2nd trimester | Avoid unless benefit outweighs risk; limited data. |
| 3rd trimester | Avoid; may cause adverse neonatal effects. |
Clinical note
Comprehensive clinical and safety monograph for OCUSULF-30 (OCUSULF-30).
| Placental transfer | Crosses placenta; evidence from animal studies. |
| Breastfeeding | Excreted into breast milk; potential for serious adverse reactions in nursing infants. Discontinue drug or nursing. |
| Lactation Rating | L5 |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentPregnancy (unless specific benefit-risk)
| Precautions | May cause gradual permanent changes in iris pigmentation, Risk of eyelid skin darkening and increased eyelash growth, Caution in patients with intraocular inflammation or macular edema, May cause blurred vision or visual disturbances |
| Food/Dietary | No known food interactions with OCUSULF-30 (sulfacetamide ophthalmic solution). No dietary restrictions are required. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk |
| FDA Pregnancy Category C. First trimester: Limited data in humans; animal studies show teratogenic effects at high doses. Second and third trimesters: Risk of fetal nephrotoxicity and pulmonary hypoplasia with chronic use. Avoid after 32 weeks gestation. |
| Fetal Monitoring | Monitor maternal renal function (serum creatinine, BUN) and urine output. Fetal monitoring with ultrasound for amniotic fluid volume and renal development. Blood pressure monitoring. |
| Fertility Effects | No specific human studies; animal studies show reduced fertility at high doses. Likely reversible upon discontinuation. |
| OCUSULF-30 (sulfacetamide sodium ophthalmic solution 30%) is used for ocular infections. For optimal efficacy, shake well before use and avoid touching the dropper tip to any surface. Prolonged use may lead to overgrowth of nonsusceptible organisms. Monitor for hypersensitivity, especially in patients with sulfonamide allergy. Do not use with silver-containing preparations due to precipitation. |
| Patient Advice | Wash hands before and after applying the eye drops. · Tilt head back, pull down lower eyelid, and instill prescribed number of drops into the conjunctival sac without touching the dropper to the eye. · Close eye gently for 1-2 minutes after instillation to enhance absorption. · Wait at least 5 minutes between using different eye drop medications. · Notify your doctor immediately if you experience eye pain, vision changes, or signs of allergy (rash, itching, swelling). |